Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis

2021/07/01 by Tananchai Petnak, Ploypin Lertjitbanjong, Charat Thongprayoon +1 · 27 citations
Medicine · #Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis #Lung Cancer Treatments and Mutations #Pulmonary Hypertension Research and Treatments

paper · doi:10.1016/j.chest.2021.06.049

Cited by

• Pulmonary Fibrosis and the TGF-β Signaling Axis: Advances in Targeted Therapeutics
• Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study
• Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. [europepmc]
• The Impact of Inflammatory Immune Reactions of the Vascular Niche on Organ Fibrosis. [europepmc]
• TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. [europepmc]
• Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. [europepmc]
• Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. [europepmc]
• Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study. [europepmc]
• Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics. [europepmc]
• What Do We Need to Know About Rising Rates of Idiopathic Pulmonary Fibrosis? A Narrative Review and Update. [europepmc]
• Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis. [europepmc]
• Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial. [europepmc]
• Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks. [europepmc]
• Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. [europepmc]
• Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients. [europepmc]
• Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies. [europepmc]
• The impact of deep learning reconstruction in low dose computed tomography on the evaluation of interstitial lung disease. [europepmc]
• Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry. [europepmc]
• Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality. [europepmc]
• Emerging delivery approaches for targeted pulmonary fibrosis treatment. [europepmc]
• A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. [europepmc]
• A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases. [europepmc]
• Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study. [europepmc]
• Drugs targeting CTGF in the treatment of pulmonary fibrosis. [europepmc]
• Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. [europepmc]
• Mortality trends in idiopathic pulmonary fibrosis in Europe between 2013 and 2018. [europepmc]
• Acute exacerbations in patients with progressive pulmonary fibrosis. [europepmc]